Successful Treatment of Aluminum Phosphide Poisoning with Continuous Veno-venous Hemofiltration: A Case Report

Year 2016, Volume: 7 Issue: 3, 53 - 55, 01.07.2016

Ayça Açıkalın Nezihat Rana Dişel Emre Karakoç Selçuk Matyar Ahmet Sebe

Abstract

Introduction: We aim to discuss the case of a patient with aluminum phosphide (AP) poisoning in a suicide attempt and who was successfully treated with continuous veno-venous hemofiltration (CVVH). Case Report: A-24-year old lady was admitted to a hospital with the complaints of dizziness, numbness in the face, and nausea and vomiting after taking two tablets of AP. She was transferred to our emergency clinic 10 h later because of persistent hypotension and metabolic acidosis. Her Glasgow Coma Scale score was 13 on admission. Her vital signs were as follows: blood pressure, 80/50 mmHg; pulse rate, 128/min; pulse oximetry, 90%; and respiration rate, 26/min. Her laboratory tests revealed the following: pH, 7.13; bicarbonate level, 10.1 mmol/L; and serum lactate level, 10.2 mmol/L. Other blood test results were normal. CVVH (Prismaflex hemofiltration set M150) was started in the intensive care unit because hypotension and metabolic acidosis were persistent; oliguria was added despite fluid resuscitation and inotrope infusion. Hemofiltration was continued until the 32nd hour when blood pressure and blood gas levels returned to normal. She was discharged healthy on the 4th day of hospitalization.Conclusion: We suggest the utilization of CVVH in the early stages of AP poisoning before the development of multiple organ failure because AP causes metabolic acidosis and hypotension resistant to medical treatment

Keywords

Aluminum phosphide, continuous veno-venous hemofiltration, poisoning

References

• Moghadamnia AA. An update on toxicology of aluminum phospide. DARU Journal of Pharmaceutical Sciences, 2012; 20: 25. [CrossRef]
• Satar S, Seydaoglu G, Akpinar A, Sebe A, Karakoc E, Gumusay U et al. Trends in acute adult poisoning in a ten-year period in Turkey: factors affecting the hazardous outcome. Bratisl Lek Listy 2009; 110: 404-11.
• Katira R, Elhence GP, Mehrotra ML, Srivastava SS, Mitra A, Agarwala R, et al. A study of aluminum phosphide (AlP) poisoning with special refer- ence to electrocardiographic changes. J Assoc Physicians India 1990; 38: 471-3.
• Mehrpour O, Jafarzadeh M, Abdollahi M. A systematic review of alu- minium phosphide poisoning. Arh Hig Rada Toksikol, 2012; 63: 61-73. [CrossRef]
• Singh D, Jit I, Tyagi S. Changing trends in acute poisoning in Chandi- garh zone: a 25-year autopsy experience from a tertiary care hospital in northern India. Am J Forensic Med Pathol, 1999; 20: 203-10. [CrossRef]
• Moghadamnia AA, Firoozjahi AR, Javadian SH, Dibavand N. Aluminium phosphide poisoning in mice and the procedure for its management. J Babol Univ Med Sci 2000; 2: 25-33.
• Chugh SN, Kolley T, Kakkar R, Chugh K, Sharma A. A critical evaluation of anti-peroxidant effect of intravenous magnesium in acute aluminium phosphide poisoning. Magnes Res 1997; 10: 225-30.
• Jadhav AP, Nusair MB, Ingole A, Alpert MA. Unresponsive ventricular tachycardia associated with aluminum phosphide poisoning. Am J Emerg Med 2012; 30: 633.e3-5. [CrossRef]
• Finkle SN. Should dialysis be offered in all cases of metformin-associat- ed lactic acidosis? Crit Care 2009; 13: 110. [CrossRef]
• Nasa P, Gupta A, Mangal K, Nagrani SK, Raina S, Yadav R. Use of continu- ous renal replacement therapy in acute aluminum phosphide poison- ing: a novel therapy. Ren Fail 2013; 35: 1170-2. [CrossRef]